Patient characteristics
Twenty-one patients with CVID (14 women and 7 men) were enrolled in the study. The mean age was 46.3 years (±9.7 SD). The mean disease duration was 9.1 years (±7.49). All patients underwent regular IRT with intravenous (IVIG: 23.8%, n=5/21) or subcutaneous (SCIG: 76.2%, n=16/21) administration, with mean dose of 287.6 mg/kg/month (± 69.6). The mean serum IgG trough level was 6.13 g/L (±1.59). Antibiotic prophylaxis was indicated in three patients with CVID (14.3%), including cotrimoxazole and macrolides. Non-infectious complications were observed in 16 patients (76.2%), and the most prevalent complications were bronchial asthma (28.6%, n=6/21), autoimmune thyroiditis (23.8%, n=5/21), enteropathy (23.8%, n=5/21), chronic lung disease (19%, n=4/21), splenomegaly (19%, n=4/21), vitiligo (19%, n=4/21), immune thrombocytopenic purpura (9.5%, n=2/21), lymphadenopathy (9.5%, n=2/21), and sarcoid-like disease (9.5%, n=2/21). Other complications were present in <2 patients, and 6 patients exhibited >2 complications. Three patients (14.3%) were on active immunosuppression with glucocorticosteroids upon vaccination, and five (23.8%) had previously received immunosuppressive therapy. Patient characteristics are summarized in Table 1.